Covaxin Is Safe, Produced Immune Response In Early Human Trial, Says The Lancet Study

New Delhi: Bharat Biotech’s COVID-19 vaccine, which has been authorised to be used in the country, is proven to be safe and produced an immune response in a small group of adults in the age group 18-55 years, a study in The Lancet medical journal said.

The vaccine, developed in association with the Indian Council of Medical Research (ICMR), is being evaluated in a separate 25,800 person trial, that kicked off in November. Bharat Biotech on Friday said that 13,000 people taking part in the late-stage trial had been given the second dose, reported news agency Reuters.

Two formulations of the vaccine, called COVAXIN, have been picked for testing in more advanced stages and further efficacy trials are warranted, the agency report said.

COVAXIN is an inactivated vaccine that introduces dead virus into the body to trigger an immune response.

ALSO READ: India To Start Exporting COVID-19 Vaccines To Six Neighbouring Countries Today